- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
-
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki , Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T
- KMID: 2417858
- Cancer Res Treat.
- 2018 Jul;50(3):691-700.
- doi: 10.4143/crt.2017.280
PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
